Bajaj Healthcare Limited has announced the appointment of Mrs. Purnima Dhanraj Amin as Additional Director in the Non-Executive Independent Director category. The appointment was approved by the Board of Directors through a resolution passed by circulation on January 05, 2026, based on the recommendation of the Nomination & Remuneration Committee.

Appointment Details

The key details of Mrs. Amin's appointment are outlined below:

Professional Background and Expertise

Mrs. Purnima Dhanraj Amin brings extensive academic and research experience to the board. She is currently a Professor of Pharmacy at the Institute of Chemical Technology (ICT), Mumbai, Maharashtra. Her educational qualifications include a B. Pharma (Pharmacy), M. Pharma (Pharmaceutics) and Ph.D. (Tech.) in Pharmaceutics from the Institute of Chemical Technology.

With over 32 years of academic and research experience at ICT, Mumbai, Mrs. Amin currently serves as Vice President-Technological Association ICT and Dean-Student and Alumni Affairs. Her major research expertise lies in the application of Hot Melt Extrusion (HME) technology for the development of innovative drug delivery systems, covering oral, topical and parenteral formulations.

Industry Experience and Recognition

Mrs. Amin serves as a consultant to the Indian pharmaceutical industry, specializing in formulation development and evaluation of drug delivery systems. She has received numerous awards and recognitions for her contributions to pharmacy education and research. Additionally, she has authored several research publications in reputed scientific journals and holds life memberships in professional and educational organizations.

Compliance and Independence Confirmation

Mrs. Amin has confirmed that she meets the criteria of independence under Section 149 of the Companies Act, 2013, and Regulation 16 of the Listing Regulations. She has also confirmed that she has not been debarred from holding the office of Director by virtue of any order passed by the Securities and Exchange Board of India or any other such authority.

The company has disclosed that Mrs. Amin is not related to any of the existing Directors of the company, ensuring her independence in the role. The appointment has been made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Bajaj Healthcare Limited has received regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) on December 31, 2025, to conduct clinical trials and bioequivalence study for Suvorexant tablets. This development marks a significant step forward in the company's pharmaceutical development pipeline.

Regulatory Milestone

The CDSCO approval enables Bajaj Healthcare to proceed with clinical testing and bioequivalence studies of Suvorexant tablets, a medication primarily used for treating sleep disorders. This regulatory clearance is essential for pharmaceutical companies seeking to bring new formulations to market, as it allows them to conduct necessary safety and efficacy studies.

Clinical Trial and Bioequivalence Study Significance

Receiving CDSCO approval represents a crucial phase in the drug development process. The approval indicates that the regulatory authority has reviewed and accepted the company's clinical trial protocol, manufacturing standards, and safety parameters for the proposed study. The bioequivalence study component will help establish that the company's formulation performs similarly to existing reference products.

Strategic Development

This approval allows Bajaj Healthcare to advance its research and development efforts in the sleep disorder treatment segment. The company can now initiate the clinical trial and bioequivalence study process, which will generate the necessary data required for eventual market authorization of the Suvorexant tablet formulation.

The CDSCO clearance demonstrates the company's adherence to regulatory standards and its commitment to following proper clinical development pathways for new pharmaceutical products.